BeBetter Med

BeBetter Med Inc., founded in January 2012 by Professor Changgeng Qian, a specially appointed expert of the "National Major Talent Project," and his team in Guangzhou Science City High-tech Industrial Development Zone, is a biopharmaceutical company focused on the independent research and development of innovative drugs guided by clinical value. The company concentrates on major disease areas such as cancer, autoimmune diseases, and metabolic diseases. Relying on its self-developed core technology platform, it continuously develops globally first-in-class drugs urgently needed in clinical settings and innovative drugs addressing unmet clinical needs. Adhering to the business philosophy of being "clinically value-oriented, focusing on original innovative drug research and development, committed to innovation, and striving for better," the company insists on independent innovation and is dedicated to developing innovative drugs with global independent intellectual property rights that are safe and effective. The company's management team, core technical personnel, and expert team include several returned overseas Ph.D.s, experts specially appointed under the National Major Talent Project, entrepreneurs, and operation management talents, possessing rich experience in domestic and international drug research and development and enterprise operation management. They have successively been selected as leading scientific talents in Guangzhou Development Zone, innovative entrepreneurial teams under Guangdong’s “Pearl River Talent Plan,” and leading entrepreneurial teams in Guangzhou. The company has been awarded the Guangdong Provincial Postdoctoral Innovation Practice Base, recognized as the Guangdong Provincial Engineering Technology Research Center for the Discovery and Industrialization of National Class I New Drugs, and rated as a Guangzhou "Future Unicorn" innovative enterprise and a Guangzhou "High Precision and Cutting-edge" enterprise.